ELI LILLY I4V-MC-JADW

By June 19, 2019 Closed

“A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of  Baricitinib (LY3009104) in Patients with Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors”

Join the discussion 6 Comments

Leave a Reply